FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2614066012> ?p ?o ?g. }

• W2614066012 endingPage "e6769" @default.
• W2614066012 startingPage "e6769" @default.
• W2614066012 abstract "Background: This study aimed to determine the maximum tolerated dose (MTD), dose-limiting toxicity, and efficacy of second-line chemotherapy with FOLFIRINOX after gemcitabine (GEM)-based chemotherapy failure in metastatic pancreatic cancer (MPC). Methods: We studied 18 histopathologically proven MPC patients. The schedule was 85 mg/m2 oxaliplatin, irinotecan, and 400 mg/m2 leucovorin, followed by 400 mg/m2 5-fluorouracil (5-FU) as a bolus on day 1 and 2400 mg/m2 5-FU as a 46-hour continuous infusion biweekly. The dose of irinotecan was defined as follows: level 0: 100 mg/m2, level 1: 125 mg/m2, level 2: 150 mg/m2, and level 3: 180 mg/m2. The doses of other drugs were fixed. The primary endpoint of phase II study was the response rate (RR). Results: We initially evaluated 6 patients in a phase I study. One patient developed neutropenia and 1 patient developed hyperglycemia and severe infection. Accordingly, level 1 was chosen as the MTD. According to a phase II study, the RR was 22.2% and the disease control rate was 61.1%. The progression-free survival and overall survival were 2.8 (range, 0.7–19.1) and 9.8 (2.4–19.8) months, respectively. The most common severe adverse event was neutropenia (66.7%). Febrile neutropenia occurred in 1 (5.6%) case. Conclusion: The recommended dose was 85 mg/m2 oxaliplatin, 100 mg/m2 irinotecan, and 400 mg/m2 leucovorin, followed by 400 mg/m2 5-FU as a bolus on day 1 and 2400 mg/m2 5-FU as a 46-hour continuous infusion. These results indicate that second-line FOLFIRINOX is a marginally effective treatment for GEM-based chemotherapy failure cases." @default.
• W2614066012 created "2017-05-19" @default.
• W2614066012 creator A5003533726 @default.
• W2614066012 creator A5012904104 @default.
• W2614066012 creator A5015408047 @default.
• W2614066012 creator A5043460153 @default.
• W2614066012 creator A5055509303 @default.
• W2614066012 creator A5061777118 @default.
• W2614066012 date "2017-05-01" @default.
• W2614066012 modified "2023-10-16" @default.
• W2614066012 title "Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure" @default.
• W2614066012 cites W1906085213 @default.
• W2614066012 cites W1931508686 @default.
• W2614066012 cites W1968812902 @default.
• W2614066012 cites W1971806112 @default.
• W2614066012 cites W2006766434 @default.
• W2614066012 cites W2023335214 @default.
• W2614066012 cites W2024598695 @default.
• W2614066012 cites W2027389238 @default.
• W2614066012 cites W2046116942 @default.
• W2614066012 cites W2054625398 @default.
• W2614066012 cites W2061132293 @default.
• W2614066012 cites W2136866696 @default.
• W2614066012 cites W2139248078 @default.
• W2614066012 cites W2147546342 @default.
• W2614066012 cites W2151253787 @default.
• W2614066012 cites W2158798157 @default.
• W2614066012 cites W2165480504 @default.
• W2614066012 cites W2187917981 @default.
• W2614066012 cites W2317471183 @default.
• W2614066012 cites W2317504614 @default.
• W2614066012 cites W2345269414 @default.
• W2614066012 cites W2590869048 @default.
• W2614066012 cites W3005597110 @default.
• W2614066012 cites W4244578979 @default.
• W2614066012 doi "https://doi.org/10.1097/md.0000000000006769" @default.
• W2614066012 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5428587" @default.
• W2614066012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28489753" @default.
• W2614066012 hasPublicationYear "2017" @default.
• W2614066012 type Work @default.
• W2614066012 sameAs 2614066012 @default.
• W2614066012 citedByCount "19" @default.
• W2614066012 countsByYear W26140660122018 @default.
• W2614066012 countsByYear W26140660122020 @default.
• W2614066012 countsByYear W26140660122021 @default.
• W2614066012 countsByYear W26140660122023 @default.
• W2614066012 crossrefType "journal-article" @default.
• W2614066012 hasAuthorship W2614066012A5003533726 @default.
• W2614066012 hasAuthorship W2614066012A5012904104 @default.
• W2614066012 hasAuthorship W2614066012A5015408047 @default.
• W2614066012 hasAuthorship W2614066012A5043460153 @default.
• W2614066012 hasAuthorship W2614066012A5055509303 @default.
• W2614066012 hasAuthorship W2614066012A5061777118 @default.
• W2614066012 hasBestOaLocation W26140660121 @default.
• W2614066012 hasConcept C121608353 @default.
• W2614066012 hasConcept C126322002 @default.
• W2614066012 hasConcept C141071460 @default.
• W2614066012 hasConcept C203092338 @default.
• W2614066012 hasConcept C2776694085 @default.
• W2614066012 hasConcept C2777063308 @default.
• W2614066012 hasConcept C2777148230 @default.
• W2614066012 hasConcept C2778850193 @default.
• W2614066012 hasConcept C2780210213 @default.
• W2614066012 hasConcept C2780258809 @default.
• W2614066012 hasConcept C2780259306 @default.
• W2614066012 hasConcept C2780962732 @default.
• W2614066012 hasConcept C31760486 @default.
• W2614066012 hasConcept C43376680 @default.
• W2614066012 hasConcept C526805850 @default.
• W2614066012 hasConcept C535046627 @default.
• W2614066012 hasConcept C71924100 @default.
• W2614066012 hasConcept C90924648 @default.
• W2614066012 hasConceptScore W2614066012C121608353 @default.
• W2614066012 hasConceptScore W2614066012C126322002 @default.
• W2614066012 hasConceptScore W2614066012C141071460 @default.
• W2614066012 hasConceptScore W2614066012C203092338 @default.
• W2614066012 hasConceptScore W2614066012C2776694085 @default.
• W2614066012 hasConceptScore W2614066012C2777063308 @default.
• W2614066012 hasConceptScore W2614066012C2777148230 @default.
• W2614066012 hasConceptScore W2614066012C2778850193 @default.
• W2614066012 hasConceptScore W2614066012C2780210213 @default.
• W2614066012 hasConceptScore W2614066012C2780258809 @default.
• W2614066012 hasConceptScore W2614066012C2780259306 @default.
• W2614066012 hasConceptScore W2614066012C2780962732 @default.
• W2614066012 hasConceptScore W2614066012C31760486 @default.
• W2614066012 hasConceptScore W2614066012C43376680 @default.
• W2614066012 hasConceptScore W2614066012C526805850 @default.
• W2614066012 hasConceptScore W2614066012C535046627 @default.
• W2614066012 hasConceptScore W2614066012C71924100 @default.
• W2614066012 hasConceptScore W2614066012C90924648 @default.
• W2614066012 hasIssue "19" @default.
• W2614066012 hasLocation W26140660121 @default.
• W2614066012 hasLocation W26140660122 @default.
• W2614066012 hasLocation W26140660123 @default.
• W2614066012 hasOpenAccess W2614066012 @default.
• W2614066012 hasPrimaryLocation W26140660121 @default.
• W2614066012 hasRelatedWork W1883975635 @default.
• W2614066012 hasRelatedWork W2429983174 @default.

• next